semaglutide supply news november 2025 Are you eligible? Medicare's new GLP-1 Bridge program will cover certain weight-loss drugs starting this week. But as of now, the program isn't permanent: https://www.wtol.com/article/news/nation-world/medicare-covering-glp-1-weight-loss-drugs-bridge The Risks of Compounded Semaglutide

While effective, it may not be ideal for everyone

Consider a total national amount of semaglutide that allows less than half of obese US adults to take 2.4 mg once weekly

The parallel STEP program (2021, NEJM) covers semaglutide

Additional scientific resources are available in the Research Library

Zepbound and Wegovy are both effective at treating obesity and approved by the US Food and Drug Administration to do so, but there are differences

There are four main physiological causes of palpitations: Extra-cardiac stimulation of the sympathetic nervous system (SNS), resulting in excess production of catecholamines and cortisol